Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice

Cancer Research

Volumn 58, Issue 1, 1998, Pages 60-64

  Couillard, Steeve ^a   Gutman, Matthieu ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Candas, Bernard ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; OVARIECTOMY; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BENZOPYRANS; BREAST NEOPLASMS; CELL DIVISION; ESTROGEN ANTAGONISTS; ESTRONE; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIECTOMY; PROPIONATES; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031964105     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Osborne, C. K., von Hoff, D. D., and Mullins, K. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res. Treat., 6: 229-235, 1985.
3. Asselin, J., and Labrie, F. Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J. Steroid Biochem., 9: 1079-1082, 1978.
4. McGuire, W. L., Carbone, P. P., Seard, M. E., and Esche, G. C. Estrogen receptors in human breast cancer: an overview. In: W. L. McGuire, P. P. Carbone, and E. P. Vollmer (eds.), Estrogen Receptors in Human Breast Cancer, pp. 1-7. New York: Raven Press, 1975.
5. Mouridsen, H., Palshof, T., Patterson, J., and Battersby, L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev., 5: 131-141, 1978.
6. Dickson, R. B., and Lippman, M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr. Rev., 8: 29-43, 1987.
7. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46: 4933-4937, 1986.
8. Dowsett, M., Macaulay, V., Gledhill, J., Ryde, C., Nicholls, J., Ashworth, A., McKinna, J. A., and Smith, I. E. Control of aromatase in breast cancer cells and its importance for tumor growth. J. Steroid Biochem. Mol. Biol., 44: 605-609, 1993.
9. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., and Labrie, F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breasts cancer cells in vitro. Int. J. Cancer, 73: 104-112, 1997.
10. Miller, W. R. Fundamental research leading to improved endocrine therapy for breast cancer. J. Steroid Biochem., 27: 477-485, 1987.
11. Labrie, F. Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118, 1991.
12. Lévesque, C., Mérand, Y., Dufour, J. M., Labrie, C., and Labrie, F. Synthesis and biological activity of new halo-steroidal antiestrogens. J. Med. Chem., 34: 1624-1630, 1991.
13. Wakeling, A. E., and Bowler, J. Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30: 141-147, 1988.
14. Labrie, C., Martel, C., Dufour, J. M., Lévesque, C., Mérand, Y., and Labrie, F. Novel compounds inhibit estrogen formation and action. Cancer Res., 52: 610-615, 1992.
15. Green, S., Walter, P., Kumar, V., Krust, V., Bornert, J. M., Argos, P., and Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond.), 320: 134-139, 1986.
16. Howell, A., DeFriend, D., Robertson, J., Blamey, R., and Walton, P. Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 29-30, 1995.
17. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., and Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47: 4355-4360, 1987.
18. Poulin, R., Mérand, Y., Poirier, D., Lévesque, C., Dufour, J. M., and Labrie, F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat., 14: 65-76, 1989.
19. Wakeling, A. E., Newboult, E., and Peters, S. W. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol., 2: 225-234, 1989.
20. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988.
21. Osborne, C. K., Coronado Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst., 87: 746-750, 1995.
22. Lykkesfeldt, A. E., and Sorensen, E. K. Effect of estrogens and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and tamoxifen resistant variant subline AL 1. Acta Oncol., 31: 131-138, 1992.
23. Howell, A., Dodwell, D. J., Laidlaw, I., Anderson, H., and Anderson, E. Tamoxifen as an agonist for metastatic breast cancer. In: A. Goldhirsch (ed.), Endocrine Therapy of Breast Cancer IV. Berlin: Springer-Verlag, 1990.
24. Howell, A., Dodwell, D. J., Anderson, H., and Redford, J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol., 3: 611-617, 1992.
25. Canney, P. A., Griffiths, T., Latief, T. N., and Priestman, T. J. Clinical significance of tamoxifen withdrawal response. Lancet, 1: 36, 1987.
26. Pritchard, K. I., Thomson, D. B., Myers, R. E., Sutherland, D. J., Mobbs, B. G., and Meakin, J. W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat. Rep., 64: 787-796, 1980.
27. Hoogstraten, B., Gad el Mawla, N., Maloney, T. R., Fletcher, W. S., Vaughn, C. B., Tranum, B. L., Athens, J. W., Costanzi, J. J., and Foulkes, M. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer (Phila.), 54: 2248-2256, 1984.
28. Wiebe, V. J., Osborne, C. K., Fuqua, S. A., and DeGregorio, M. W. Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14: 173-188, 1993.
29. Brunner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., and Clarke, R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3232, 1993.
30. Lykkesfeldt, A. E., Madsen, M. W., and Briand, P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line MCF-7/TAMR-1. Cancer Res., 54: 1587-1595, 1994.
31. Coopman, P., Garcia, M., Brunner, N., Derocq, D., Clarke, R., and Rochefort, H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int. J. Cancer, 56: 295-300, 1994.
32. Gottardis, M. M., Jiang, S. Y., Jeng, M. H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49: 4090-4093, 1989.
33. Osborne, C. K., Coronado, E. B., Allred, D. C., Wiebe, V., and DeGregorio, M. Acquired tamoxifen (TAM) resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydrotamoxifen. J. Natl. Cancer Inst., 83: 1477-1482, 1991.
34. Dauvois, S., Geng, C. S., Lévesque, C., Mérand, Y., and Labrie, F. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51: 3131-3135, 1991.
35. Conover, W. J. Contingency tables. Practical nonparametric statistics, Ed. 2, pp. 153-170. New York: John Wiley & Sons, 1980.
36. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., and Labrie, F. Highly potent and pure antiestrogenic activity of a new antiestrogen on human ZR-75-1 breast tumors in nude mice. Proceedings of the Endocrine Society Meeting, San Francisco, pp. 604, 1996.
37. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., and Wakeling, A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol., 34: 89-95, 1994.
38. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23: 1189-1196, 1987.
39. Osborne, C. K., Wiebe, V. J., McGuire, W. L., Ciocca, D. R., and DeGregorio, M. W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Clin. Oncol., 10: 304-310, 1992.
40. Weaver, C. A., Springer, P. A., and Katzenellenbogen, B. S. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Mol. Endocrinol., 2: 936-945, 1988.
41. Nomura, Y., Tashiro, H., and Hisamatsu, K. Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar. J. Natl. Cancer Inst., 82: 1146-1149, 1990.
42. DeFriend, D. J., Anderson, E., Bell, J., Wilks, D. P., West, C. M., Mansel, R. E., and Howell, A. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer, 70: 204-211, 1994.
43. Wakeling, A. E. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem., 34: 183-188, 1989.
44. Darbre, P. D., Curtis, S., and King, R. J. Effects of estradiol and tamoxifen on human breast cancer cells in serum-free culture. Cancer Res., 44: 2790-2793, 1984.
45. Reddel, R. R., and Sutherland, R. L. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur. J. Cancer Clin. Oncol., 20: 1419-1424, 1984.
46. Roos, W., Huber, P., Oeze, L., and Eppenberger, U. Hormone dependency and the action of tamoxifen in human mammary carcinoma cells. Anticancer Res., 2: 157-162, 1982.
47. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA, 83: 2496-2500, 1986.
48. Cormier, E. M., and Jordan, V. C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur. J. Cancer Clin. Oncol., 25: 57-63, 1989.
49. Furr, B. J., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205, 1984.
50. Plotkin, D., Lechner, J. J., Jung, W. E., and Rosen, P. J. Tamoxifen flare in advanced breast cancer. J. Am. Med. Assoc., 240: 2644-2646, 1978.
51. McIntosh, I. H., and Thynne, G. S. Tumor stimulation by anti-oestrogens. Br. J. Surg., 64: 900-901, 1977.
52. Clarysse, A. Hormone-induced tumor-flare. Eur. J. Cancer Clin. Oncol 27-545-547 1985.
53. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S. M., Mérand, Y., Bélanger, A., Labrie, C., and Labrie, F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497, 1997.